BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Jun 17, 2024
- Significant YoY improvement in operating performance -
- Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities -
Read more at globenewswire.com
